Thoracic and Lung Cancer
Research activity includes non-small cell lung cancer across operable, locally advanced, metastatic, and stage IV settings, as well as small cell lung cancer in extensive-stage disease. The portfolio also extends to early-stage and resected lung cancer, with attention to immunotherapy and combination treatment approaches.
- Non-small cell lung cancer
- Small cell lung cancer
- Early-stage and resected lung cancer
- Metastatic thoracic malignancies
These studies reflect sustained interest in lung cancer control across both curative-intent and advanced disease settings.
Melanoma and Other Solid Tumours
The sponsor supports research in melanoma, including completely resected stage II and stage III/IV disease, alongside broader programs in advanced solid tumours. Additional interest spans head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, pancreatic cancer, and bladder cancer.
- Melanoma
- Advanced solid tumours
- Head and neck squamous cell carcinoma
- Esophageal and gastric cancers
Several programs focus on disease recurrence, residual disease after resection, and treatment options for late-line metastatic cancer.
Genitourinary and Hepatic Oncology
Clinical research includes renal cell carcinoma, metastatic castration-resistant prostate cancer, urothelial carcinoma, and bladder cancer. The sponsor also studies advanced hepatocellular carcinoma, including patients with unresectable or metastatic liver cancer.
- Renal cell carcinoma
- Prostate cancer
- Urothelial and bladder cancer
- Hepatocellular carcinoma
This area includes both first-line and previously treated disease populations, with emphasis on immune-based and combination strategies.
Gastrointestinal and Colorectal Cancer
The research portfolio covers metastatic colorectal cancer, including MSI-positive and MSI-negative colorectal cancer, as well as esophageal and gastroesophageal junction cancer. Studies also address later-line treatment needs in advanced gastrointestinal malignancies.
- Colorectal cancer
- Esophageal and gastroesophageal junction cancer
- Gastric cancer
- Advanced gastrointestinal malignancies
Research in this domain includes biomarker-informed populations and post-surgical disease management.
Hematologic Malignancies and Immune-Mediated Disease
Investigator programs include classical Hodgkin lymphoma, non-Hodgkin lymphoma, chronic myeloid leukemia, and Philadelphia chromosome-positive leukemias in pediatric and adolescent populations. The sponsor also funds work in multiple myeloma and systemic lupus erythematosus.
- Hodgkin and non-Hodgkin lymphoma
- Chronic myeloid leukemia
- Multiple myeloma
- Systemic lupus erythematosus
These studies span both oncology and autoimmune disease, with attention to pediatric, relapsed, and treatment-resistant settings.
